Fewer than 10% of people that would benefit from GLP-1 drugs including Wegovy are able to get them, states the WHO as it issues its initial guidance on the drugs.
Considering over a billion individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
According to projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be addressed with holistic and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major barriers to broad access to the jabs that can help people shift significant body mass, notes the body.
Weight-Loss Drug Scarcity
Even in the current most favorable scenario, the production of such drugs might only reach approximately 100 million people – under 10% of the global need, as stated by the health organization.
The guideline urges countries and companies to increase access, by strategies such as licensing agreements.
A patent on semaglutide – the core component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and boost feelings of fullness so people eat less.
Individuals typically see weight reduction in the initial weeks of commencing the weekly injections.
Research indicates patients may regain a significant portion after a year of discontinuing the drug, when their typical hunger come back.
To be overweight or obese elevates your likelihood for contracting diseases, including diabetes, heart disease, stroke, and some cancers.
Obesity concerns people in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the WHO.
